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THE goal of tolerance induction, although achievable in pre-clinical models, is not yet a clinical reality. One of 
the most important areas of experimental research in thc 
field of tolerance induction has been the administration of 
donor-specific bone marrow in conjunction with whole 
organ transplantation. The same strategy has been tested in 
several clinical trials; all have included chronic immunosup-
pression as well. 
This paper will review briefly the major published expe-
rience to date with bone marrow augmentation in renal 
transplantation, with passing reference to observations in 
pre-clinical experimental models. Although the results do 
not portend the end of the need for chronic non-specific 
immunosuppression, they suggest that bone marrow aug-
mentation is reasonably safe, has an impact on chimerism 
and perhaps the outcome after transplantation, and may 
have a role in future immunosuppressive regimens. 
SIGNIFICANCE OF CHIMERISM 
The various efforts to augment the characteristic spontane-
ous microchimerism of whole organ transplantation can 
best be understood in the context provided by Starzl and 
Zinkernagel described earlier at this meeting. 1 In this 
concept, graft acceptance is analogous to an infectious 
carrier state and is accounted for by two straightforward 
mechanisms, both of which are governed by the migration 
and localization of the antigen, as opposed to the antigen 
per se. The first mechanism is T-cell (and probably also 
B-cell) clonal activation and then exhaustion (so called 
activation-associated tolerance) which occur exclusively in 
lymphoid organs or organized lymphoid coliections. I- 3 
The second mechanism is immune indifference which re-
quires movement of the live antigen to "hide outs" that are 
inaccessible to cytotoxic T lymphocytes and neutralizing anti-
bodies.3-6 Because the antigenic passenger leukocytes of 
organ grafts are widely disseminated and replaced by recipient 
leukocytes, "indifference" could occur peripherally, at the level 
of the graft, or at both sites. Negative regulators (ie, suppres-
sor cells, veto cells, cytokine profile changes) may play an 
accessory role, but they are not essential. 1.3 
EXPERIENCE WITH ADJUNCT BONE MARROW IN 
ORGAN TRANSPLANTATION 
It was not recognized until 1992 that whole-organ trans-
plantation involved engraftment of migratory antigen (ie, 
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passenger leukocytes producing microchimerism). Never-
theless, the induction of chimerism has been a historical 
theme of transplant research ever since the chimeric state 
was associated with acquired tolerance by Billingham et al.7 
in their neonatal mouse model. 
The Monaco Model 
Some of the earliest and perhaps the most influential work 
in this area has been that of Monaco and his associates. His 
pre-clinical model involved the administration of induction 
antilymphocyte preparations and delayed infusion of bone 
marrow 2 to 31/2 weeks after transplantation.8 - 12 Monaco 
applied this strategy clinically in a 38-year-old sensitized 
patient who underwent cadaveric kidney transplantation in 
1973, followed 25 days later by an intravenous infusion of 
cryopreserved donor bone marrow. \3 Immunosuppression 
was with azathioprine, ALG, and prednisone. 
Donor cells in the peripheral blood were undetectable 2 
months after transplantation. The patient had a relatively 
benign postoperative course for 8 months, with normal 
renal function and only one episode of mild histologic 
rejection (prior to bone marrow infusion); there was no 
evidence of graft versus host disease (GVHD). She then 
developed a perforated sigmoid diverticulitis, from which 
she died. At autopsy, there was no evidence of rejection. 
Approximately a decade later, encouraged by Judy Tho-
mas's work with the primate model,14.15 Monaco performed 
three living-related kidneylbone marrow transplantations, 
using the same triple drug induction therapy (including 
ALG) and administration of 3 to 5 X 108 cryopreserved 
bone marrow cells/kg on postoperative day 21. 16 Two of the 
recipients did well; with no evidence of rejection at 11 and 
13 months after transplantation, and had evidence of 
decreasing donor-specific responsiveness. The third allo-
graft was lost to patient non-compliance. 
The first large-scale trial of kidneylbone marrow trans-
plantation with the Monaco model was carried out in 
Birmingham, Alabama by Barber and his colleagues under 
cyclosporine-based immunosuppression. Fifty-seven pa-
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tients received cadaver kidneys with induction antilympho-
cyte therapy. and delayed (postoperative day 17-21) bone 
marrow infusion.17 Fifty-four recipients of the contralateral 
kidneys were studied as controls. although assignment to 
the bone marrow and control groups was not formally 
randomized. 
The bone marrow group had significantly better graft 
survival at 12 and 18 months (90% and 85% respectively) 
than the control group (71 % and 67%). There also was a 
trend toward decreasing donor-specific reactivity in the 
bone marrow group. In a later study, less rejection was 
described in the recipients of adjunct bone marrow in whom 
blood chimerism was detectable. I!! and 1 year after trans-
plantation, peripheral blood chimerism was seen in 56% of 
the bone marrow-treated patients, and 21 % of the control 
patients. Barber and his group concluded that bone marrow 
augmentation was a useful modality. 
The Miami kidney transplant experience of Miller and his 
associates under tacrolimus-based immunosuppression is 
discussed here, out of chronological order, because a mod-
ified Monaco strategy of induction antilymphocyte therapy 
with delayed bone marrow infusion was used. In their first 
40 patients, two doses of cryopreserved marrow were given, 
the first between postoperative days 1 and 4 and the second 
between postoperative days 10 and 14.19 In addition to 
tacrolimus and steroids, some of the patients were admin-
istered mycophenolate mofetil (MMF). 
As in the Boston and Alabama experiences, this was a 
non-randomized trial. A comparison was made with 100 
concurrent kidney recipients not receiving bone marrow. 
The observations included: (1) a ten-fold increase in donor 
cell chimerism in the recipient bone marrow; (2) less 
peripheral blood chimerism in bone marrow recipients 
experiencing rejection; (3) higher levels of chimerism in 
HLA DR identical recipients; and (4) the presence of 
pluripotent and/or precursor donor cells in recipient pe-
ripheral blood and bone marrow. This last finding has also 
been described by Rao et al. in liverlbone marrow recipi-
ents.20•21 
There was, however, an unexpectedly higher mortality in 
the bone marrow group, and a higher incidence of viral 
complications. Although this was of concern to the Miami 
group, heightened morbidity or mortality has not been 
observed in subsequent cases, nor any graft losses to 
rejection (1. Miller, personal communication). 
The Slavin/Strober and Sachs/lJdstad Models 
The pre-clinical studies of these foregoing investigators 
represented cumulatively important contributions to the 
field. Slavin et al. 22 used recipient total lymphoid irradiation 
and bone marrow infusion to induce incomplete chimerism 
and stable tolerance in rodents. Because the cytoreduction 
left a substantial portion of the recipient immune function 
intact, the tolerance was achieved without OVHD. A small 
number of immunologically high risk cadaveric kidney 
transplantations were done with this approach in the pre-
cyclosporine era,23.24 but the series was terminated because 
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of excessive morbidity and because the recipients, who were 
selected on the basis of high immunobiologic risk factors, 
could be better and more efficiently treated with cyclospo-
rine-based immune suppression. 
The work of Sachs and Ildstad is mentioned here for the 
sake of completeness, although there have been no pub-
lished clinical applications. Both of these investigators used 
supra- or sublethal total body irradiation with hematolym-
phopoietic reconstitution with an infusion of mixed donor 
and recipient bone marrow to achieve partial chimerism 
and stable tolerance in mice without OVHD.25 
The Pittsburgh Model 
The origins of the Pittsburgh program in bone marrow 
augmentation began with the discovery that alllong-surviv-
ing kidney (n = 5; 10 to 29 years) and liver (n = 25; 3 to 22 
years) recipients had evidence of peripheral microchimer-
ism in at least one of the following sites: skin, lymph nodes, 
and/or peripheral blood. 1,2.26 These findings led to the 
development of the two-way paradigm to explain the im-
munologic relationship between the donor and the recipi-
ent1.2•27 and ultimately to the StarzVZinkernagel explana-
tion of acquired immunologic tolerance? 
At the beginning, the simplistic therapeutic assumption 
was that if microchimerism was essential for long-term graft 
survival, the long-term prognosis, including achievement of 
drug-free tolerance, might be improved by augmenting the 
spontaneous chimerism with perioperative donor bone 
marrow. Thus, bone marrow augmentation without recipi-
ent preconditioning was begun in December 1992, and has 
been done with all of the transplantable organs (kidney, 
pancreas, islets, liver, heart, lung, and intestine).28-32 
As with all of the other reported experiences, the logistic 
difficulties of bone marrow procurement have militated 
against a randomized trial, and in fact the only randomized 
trial of bone marrow augmentation is being performed in 
Miami, in liver recipients.33 Between December 1992 and 
October 1996, 86 cases of bone marrow augmentation were 
accrued among the nearly 800 kidney transplantations at 
our center. 
The Pittsburgh strategy, in which conventional tacroli-
mus-based immune suppression was used, has differed from 
previous models in that it attempted to mimic the condi-
tions leading to spontaneous microchimerism, Thus, the 
recipient is not preconditioned before arrival of the bone 
marrow (prior immune suppression. cytoreduction, or cy-
toablation). Instead, a dose of 3 to 5 X 108 fresh unmodified 
bone marrow is given at the time of organ transplantation. 
Although we believe that microchimerism is a require-
ment for long-term organ allograft acceptance,I,2.26.27 there 
are limitations to the chimerism-inducing strategies, Recip-
ient hematolymphopoietic cytoreduction or cytoablation 
unquestionably enhances the ease and extent of donor 
leukocyte engraftment, but the potential penalty with each 
further increment in cytoreduction is proportionate weak-
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ening of the biologic safcty device (against GVHD and 
rejection) that is provided hy the nullification effect of the 
dual cell populations.3-1 as has been learned with conven-
tional bone marrow allotransplantation. 
The use of multiple bone marrow doses increases the 
level of ehimerism.3s but to the extent donor specific 
nonreactivity is induced with the early infusions. subsequent 
ones place the recipient at jeopardy from GVHD as in a 
parent to defenseless offspring FI hybrid experiment:,6.37 In 
the first 200 bone marrow augmented liver recipients. there 
were no examples of clinically significant GVHD. The 18th 
patient given divided bone marrow doses in a modification 
of the main protocol died of uncontrollable GVHD. 
Our results with the conservative single perioperative 
bone marrow dose in cadaver kidney recipients have been 
encouraging: 100% I-year and 98% 3-year actuarial patient 
survival. and a 97% and 87% 1- and 3-year actuarial graft 
survival. Control patients have had 1- and 3-year actuarial 
patient survival of 95% and 85% (P < .03) and 1- and 
3-year actuarial graft survival of 92% and 82% (P = ns). 
Late peripheral blood chimerism has been demonstrable in 
91 % of the bone marrow recipients and 51 % of the control 
patients (P < .00001 ).38 
The incidence of acute rejection. delayed graft function, 
cytomegalovirus infection. and the quality of graft function 
have been similar in the bone marrow and the control 
groups. Decreasing donor-specific reactivity has been com-
parable and has been seen in 43% of the bone marrow and 
41 % of the control patients. GVHD has not been observed. 
CONCLUSIONS 
Chimerism has been augmented in all reported series, 
although at a low level. Long-term outcomes are not yet 
available. although in some series chronic rejection has 
remained a problem. The ultimate effect of bone marrow 
augmentation will await further studies and more follow-up 
of current patients. It seems apparent. however. that bone 
marrow augmentation in transplantation is clinically feasi-
ble. reasonably safe. and may well play an important role in 
immunosuppressive strategies of the future. 
With appreciation of the commonality of infectious and 
transplantation tolerance.3 it may be possible to develop 
better strategies to augment chimerism. Although it is clear 
that chimerism is responsible for tolerance by the principal 
early mechanism of clonal exhaustion/deletion. the role of 
the immune indifference discussed by Starzl and Zinkerna-
gel is less clear and may be equally subject to biologic 
immune modulation. 
It is probable. as discussed elsewhere;,7.39 that the cur-
rent cumbersome and expensive techniques of adjunct bone 
marrow infusion can be replaced by systemic treatment with 
hematolymphopoietic growth factors (eg, G-CSF. GM-
CSF. or Fit ligand).40 If so. all the lessons currently being 
learned with the infusion techniques. including appropriate 
1373 
timing. should he applicable to the pharmacological ap-
proach to enhancement of chimerism.34.J7 
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